Comparison of the effects of transdermal and oral rivastigmine on cognitive function and EEG markers in patients with Alzheimer’s disease

Comparison of the effects of transdermal and oral rivastigmine on cognitive function and EEG markers in patients with Alzheimer’s disease

Background: Alzheimer’s disease (AD) is the most common cause of dementia in older patients. Rivastigmine (RV, Exelon, Novartis), a reversible cholinesterase inhibitor, improves clinical manifestations of AD and may enhance ACh-modulated electroencephalogram (EEG) alpha frequency. This pilot study a...

Full description

Bibliographic Details
Main Authors:	Moretti, Davide V., Frisoni, Giovanni B., Binetti, Giuliano, Zanetti, Orazio
Format:	Online
Language:	English
Published:	Frontiers Media S.A. 2014
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4107674/

Similar Items

Anatomical Substrate and Scalp EEG Markers are Correlated in Subjects with Cognitive Impairment and Alzheimer's Disease
by: Moretti, Davide V., et al.
Published: (2011)

Behavioral and Neurophysiological Effects of Transdermal Rotigotine in Atypical Parkinsonism
by: Moretti, Davide Vito, et al.
Published: (2014)

EEG upper/low alpha frequency power ratio relates to temporo-parietal brain atrophy and memory performances in mild cognitive impairment
by: Moretti, Davide V., et al.
Published: (2013)

Analysis of grey matter in thalamus and basal ganglia based on EEG α3/α2 frequency ratio reveals specific changes in subjects with mild cognitive impairment
by: Moretti, Davide V, et al.
Published: (2012)

Increase of theta frequency is associated with reduction in regional cerebral blood flow only in subjects with mild cognitive impairment with higher upper alpha/low alpha EEG frequency power ratio
by: Moretti, Davide V., et al.
Published: (2013)

Rotigotine is safe and efficacious in Atypical Parkinsonism Syndromes induced by both α-synucleinopathy and tauopathy
by: Moretti, Davide Vito, et al.
Published: (2014)

Quantitative EEG Markers in Mild Cognitive Impairment: Degenerative versus Vascular Brain Impairment
by: Moretti, D. V., et al.
Published: (2012)

Specific EEG Changes Associated with Atrophy of Hippocampus in Subjects with Mild Cognitive Impairment and Alzheimer's Disease
by: Moretti, D. V., et al.
Published: (2012)

Effectiveness and tolerability of transdermal rivastigmine in the treatment of Alzheimer’s disease in daily practice
by: Seibert, Johannes, et al.
Published: (2012)

Efficacy and Safety of Switching from Oral Cholinesterase Inhibitors to the Rivastigmine Transdermal Patch in Patients with Probable Alzheimer's Disease
by: Han, Hyun Jeong, et al.
Published: (2011)

Third degree atrioventricular block associated with treatment with rivastigmine transdermal patch
by: Knudtzen, Fredrikke C., et al.
Published: (2013)

Preparation and Characterization of Rivastigmine Transdermal Patch Based on Chitosan Microparticles
by: Sadeghi, Mohsen, et al.
Published: (2016)

Characteristics of patients with Alzheimer’s disease who switch to rivastigmine transdermal patches in routine clinical practice
by: López-Pousa, Secundino, et al.
Published: (2013)

A prospective non-interventional study for evaluation of quality of life in patients with Alzheimer’s disease treated with rivastigmine transdermal patch
by: Vagenas, Vassileios, et al.
Published: (2015)

The transdermal formulation of rivastigmine improves caregiver burden and treatment adherence of patients with Alzheimer's disease under daily practice conditions
by: Adler, G, et al.
Published: (2014)

Theta and alpha EEG frequency interplay in subjects with mild cognitive impairment: evidence from EEG, MRI, and SPECT brain modifications
by: Moretti, Davide V.
Published: (2015)

Volumetric Differences in Mapped Hippocampal Regions Correlate with Increase of High Alpha Rhythm in Alzheimer's Disease
by: Moretti, D. V., et al.
Published: (2011)

Domperidone effective in preventing rivastigmine-related gastrointestinal disturbances in patients with Alzheimer’s disease
by: Kano, Osamu, et al.
Published: (2013)

Potential therapeutic effect of nanobased formulation of rivastigmine on rat model of Alzheimer’s disease
by: Ismail, Manal Fouad, et al.
Published: (2013)

Combination of Cholecalciferol and Rivastigmine Improves Cognitive Dysfunction and Reduces Inflammation in STZ Induced Alzheimer's Model Experimentally in Rats
by: Amany N. Ibrahim, et al.
Published: (2018-07-01)

Association of EEG, MRI, and regional blood flow biomarkers is predictive of prodromal Alzheimer’s disease
by: Moretti, Davide Vito
Published: (2015)

Alzheimer's Disease: Differences of Transdermal versus Oral Treatment on Caregiving Time
by: Riedel, O., et al.
Published: (2012)

Transdermal donepezil on the treatment of Alzheimer’s disease
by: Sozio, Piera, et al.
Published: (2012)

Acquired Localized Hypertrichosis Induced by Rivastigmine
by: Imbernón-Moya, Adrian, et al.
Published: (2016)

Biomarker-based diagnosis of mild cognitive impairment due to Alzheimer’s disease: how and what to tell. A kickstart to an ethical discussion
by: Porteri, Corinna, et al.
Published: (2014)

Mild Cognitive Impairment: Structural, Metabolical, and Neurophysiological Evidence of a Novel EEG Biomarker
by: Moretti, Davide Vito
Published: (2015)

Direct Asymmetric Reductive Amination for the Synthesis of (S)-Rivastigmine
by: Guorui Gao, et al.
Published: (2018-08-01)

Understanding early dementia: EEG, MRI, SPECT and memory evaluation
by: Moretti, Davide Vito
Published: (2015)

Rivastigmine: an open-label, observational study of safety and effectiveness in treating patients with Alzheimer's disease for up to 5 years
by: Farlow, Martin R, et al.
Published: (2005)

EXACT: rivastigmine improves the high prevalence of attention deficits and mood and behaviour symptoms in Alzheimer's disease*
by: Gauthier, S, et al.
Published: (2007)

The Effect of Vascular Risk Factors on the Efficacy of Rivastigmine Patch and Capsule Treatment in Alzheimer's Disease
by: Farlow, M.R., et al.
Published: (2011)

Pharmacogenetic Study on the Effect of Rivastigmine on PS2 and APOE Genes in Iranian Alzheimer Patients
by: Zamani, M., et al.
Published: (2011)

Two cases of Alzheimer’s disease showing deterioration of behavioral and psychological symptoms of dementia induced by switching from rivastigmine to donepezil
by: Kimura, Takemi, et al.
Published: (2013)

Rivastigmine in moderately severe-to-severe Alzheimer’s disease: Severe Impairment Battery factor analysis
by: Ferris, Steven, et al.
Published: (2013)

Effects of a Rivastigmine Patch on Self-Care Activities in Patients with Alzheimer's Disease plus Cerebrovascular Disease
by: Kim, Yong Kyun, et al.
Published: (2014)

Slowing of EEG Background Activity in Parkinson’s and Alzheimer’s Disease with Early Cognitive Dysfunction
by: Benz, Nina, et al.
Published: (2014)

Editorial: Neurophysiology in Alzheimer's Disease and Dementia
by: Moretti, Davide V.
Published: (2016)

Cognitive Impairment and Electroconvulsive Therapy in Geriatric Depression, What Could be the Role of Rivastigmine? A Case Series
by: van Schaik, Audrey Monica, et al.
Published: (2015)

Effect of Rivastigmine on Behavioral and Psychiatric Symptoms of Parkinson’s Disease Dementia
by: Oh, Yoon-Sang, et al.
Published: (2015)

Progranulin Mutations Affects Brain Oscillatory Activity in Fronto-Temporal Dementia
by: Moretti, Davide V., et al.
Published: (2016)